ENDRA Life Sciences Inc. (NDRA) Latest Filing Signal

Based on earningsVibe SuperAnalyst™ synthesis of the latest 10-K, ENDRA Life Sciences Inc.'s filing signal continuing negative.

ENDRA Life Sciences Inc. is developing a next-generation enhanced ultrasound technology platform called TAEUS(R) for non-invasive assessment of liver fat, a key biomarker for metabolic diseases like MASLD and MASH. The company aims to provide a scalable, point-of-care solution to address the growing global health crisis of steatotic liver disease, for which current diagnostic tools are often expensive or invasive. ENDRA's go-to-market strategy targets pharmaceutical companies, high-end primary care networks, bariatric/metabolic clinics, and general internal medicine practices. The business model is planned as a multi-year, subscription-based offering with recurring revenue, supplemented by capital equipment sales and service agreements. In parallel, ENDRA has initiated a Digital Asset Treasury (DAT) initiative to optimize capital preservation and generate returns through investments in decentralized finance assets.

Revenue is expected to be driven by a multi-year, subscription-based business model with recurring monthly revenue, supplemented by traditional capital equipment sales and associated service and upgrade offerings for its TAEUS platform.